Literature DB >> 1854617

The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia.

A D Pearson1, H A Amineddine, M Yule, S Mills, D R Long, A W Craft, J M Chessells.   

Abstract

Sequential methotrexate (Mtx) absorption studies were undertaken in 127 children undergoing treatment for childhood non-T acute lymphoblastic leukaemia (ALL) to determine whether serum drug concentration, clearance and dosage affect event free survival (EFS). Higher serum concentration and area under the plasma concentration curve (AUC) were not associated with an improved EFS. Methotrexate clearance was not found to be of prognostic significance. Patients who tolerated only low 6-mercaptopurine (6-MP) doses because of neutropaenia and those who randomly were prescribed higher doses of Mtx had a lower rate of leukaemia relapse after the completion of therapy. This suggests that the use of maintenance therapy in maximally tolerated doses may be associated with an increased survival in childhood ALL.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1854617      PMCID: PMC1977331          DOI: 10.1038/bjc.1991.263

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

Review 1.  Polyglutamation of methotrexate. Is methotrexate a prodrug?

Authors:  B A Chabner; C J Allegra; G A Curt; N J Clendeninn; J Baram; S Koizumi; J C Drake; J Jolivet
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

2.  Drug dosage and remission duration in childhood lymphocytic leukemia.

Authors:  D Pinkel; K Hernandez; L Borella; C Holton; R Aur; G Samoy; C Pratt
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

Review 3.  The importance of dose intensity in chemotherapy of metastatic breast cancer.

Authors:  W Hryniuk; H Bush
Journal:  J Clin Oncol       Date:  1984-11       Impact factor: 44.544

4.  A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy.

Authors:  P Carde; F R MacKintosh; S A Rosenberg
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

5.  Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia.

Authors:  A D Pearson; S Mills; H A Amineddine; D R Long; A W Craft; J M Chessells
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis.

Authors:  V M Whitehead; D S Rosenblatt; M J Vuchich; J J Shuster; A Witte; D Beaulieu
Journal:  Blood       Date:  1990-07-01       Impact factor: 22.113

7.  Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia.

Authors:  W E Evans; W R Crom; C F Stewart; W P Bowman; C H Chen; M Abromowitch; J V Simone
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

8.  Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia.

Authors:  J M Chessells; A D Leiper; K Tiedemann; R M Hardisty; S Richards
Journal:  Arch Dis Child       Date:  1987-02       Impact factor: 3.791

9.  Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect.

Authors:  W E Evans; W R Crom; M Abromowitch; R Dodge; A T Look; W P Bowman; S L George; C H Pui
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

10.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.

Authors:  L Lennard; J S Lilleyman; J Van Loon; R M Weinshilboum
Journal:  Lancet       Date:  1990-07-28       Impact factor: 79.321

View more
  7 in total

1.  Maintenance treatment and shared care in lymphoblastic leukaemia.

Authors:  J M Chessells
Journal:  Arch Dis Child       Date:  1995-10       Impact factor: 3.791

2.  Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma.

Authors:  T Pignon; B Lacarelle; F Duffaud; P Guillet; J Catalin; A Durand; S Monjanel; R Favre
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 3.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

4.  Induction of acute lymphocytic leukemia differentiation by maintenance therapy.

Authors:  T L Lin; M S Vala; J P Barber; J E Karp; B D Smith; W Matsui; R J Jones
Journal:  Leukemia       Date:  2007-07-05       Impact factor: 11.528

Review 5.  An odyssey in search of a cure: the evolution of treatment of childhood acute lymphoblastic leukemia in the United Kingdom.

Authors:  V Saha; T Eden
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

6.  Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination.

Authors:  Yu Wang; Cai-Qin Wang; Peng Sun; Pan-Pan Liu; Hang Yang; Han-Yu Wang; Hui-Lan Rao; Su Li; Wen-Qi Jiang; Jia-Jia Huang; Zhi-Ming Li
Journal:  Front Oncol       Date:  2022-01-24       Impact factor: 6.244

Review 7.  Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.

Authors:  Kjeld Schmiegelow; Stine N Nielsen; Thomas L Frandsen; Jacob Nersting
Journal:  J Pediatr Hematol Oncol       Date:  2014-10       Impact factor: 1.289

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.